Thomas A Buchholz Selected Research

Drug Therapy (Chemotherapy)

02/2008	Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
12/2007	Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy.
12/2007	Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy.
07/2007	Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
01/2007	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
12/2006	African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy.
11/2006	Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy.
07/2006	Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
12/2005	The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
10/2005	Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
08/2005	Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
06/2005	Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
06/2005	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
12/2004	Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
11/2004	Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
06/2004	Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
05/2004	T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
10/2003	Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
10/2003	Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
09/2003	Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.
03/2003	Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
01/2003	Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.
11/2002	Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
06/2002	Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.

Articles by Research Topic

Disease

31	Breast Neoplasms (Breast Cancer) 02/2008 - 01/2002
6	Neoplasms (Cancer) 12/2007 - 07/2002
5	Carcinoma (Carcinomatosis) 08/2005 - 06/2002
2	Noninfiltrating Intraductal Carcinoma (DCIS) 03/2004 - 11/2002
1	Ductal Carcinoma 10/2007
1	Neoplasm Metastasis (Metastasis) 10/2005
1	Death (Near-Death Experience) 03/2005
1	Seminoma 12/2004
1	Pneumonia (Pneumonitis) 11/2004

Drug/Important Bio-Agent (IBA)

6	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2007 - 10/2003
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2007 - 11/2004
3	Epidermal Growth Factor Receptor (EGF Receptor)IBA 01/2007 - 06/2005
2	Epirubicin (Ellence)FDA LinkGeneric 01/2007 - 06/2005
2	trastuzumab (Herceptin)FDA Link 01/2007 - 06/2005
1	Radio-Opaque (Boston Post)IBA 12/2007
1	130-nm albumin-bound paclitaxelIBA 03/2007
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2007
1	Fluorouracil (Carac)FDA LinkGeneric 01/2007
1	Transcription Factors (Transcription Factor)IBA 12/2005
1	polyphenolsIBA 11/2005
1	tau Proteins (tau Protein)IBA 06/2005
1	Tamoxifen FDA LinkGeneric 03/2004
1	Protein Kinases (Protein Kinase)IBA 02/2004
1	NF-kappa B (NF-kB)IBA 11/2003
1	Estrogens (Estrogen)FDA Link 07/2003
1	RNA (Ribonucleic Acid)IBA 06/2003
1	Cyclin EIBA 11/2002
1	Biological Markers (Surrogate Marker)IBA 06/2002

Therapy/Procedure

24	Drug Therapy (Chemotherapy) 02/2008 - 06/2002
11	Mastectomy (Mammectomy) 12/2007 - 01/2002
3	Neoadjuvant Therapy 01/2008 - 06/2005
2	Segmental Mastectomy (Lumpectomy) 10/2007 - 11/2002
2	Adjuvant Radiotherapy 10/2005 - 03/2005
1	Aftercare (After-Treatment) 12/2004
1	Mammaplasty (Breast Reconstruction) 10/2002
1	Adjuvant Chemotherapy 07/2002